Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment 4-10, with additional Pro-Gly-Pro modifications designed to enhance stability and bioavailability. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax has been the subject of extensive neurological and cognitive research for several decades.
Semax was developed during the 1980s and 1990s by a research team led by Nikolai Myasoedov at the Russian Academy of Sciences. Since its introduction, the compound has been examined in hundreds of published studies involving neurobiology, cognitive performance, and neuroprotective signaling pathways.
This extensive body of literature has positioned Semax as one of the most researched peptides within the nootropic and neuroregulatory category.
Research has identified several mechanisms associated with Semax activity. One of the most studied involves its influence on brain-derived neurotrophic factor (BDNF) expression, particularly within hippocampal and cortical regions involved in learning and memory.
Additional studies have examined Semax’s interaction with melanocortin signaling, dopaminergic and serotonergic pathways, and enzymes involved in neuropeptide metabolism and degradation.
Semax is commonly administered through intranasal delivery, a method studied for its ability to facilitate direct central nervous system access through olfactory and trigeminal pathways. Pharmacokinetic research has examined how this route may support rapid CNS bioavailability while bypassing portions of the blood-brain barrier.
Published research has explored Semax in studies involving cognitive function, memory formation, attention, executive function, neuroprotection, and immune signaling. Experimental models have also examined its role in cerebrovascular research and neurotrophic factor expression including BDNF and NGF pathways.
Researchers continue to investigate Semax within broader neurobiological and cognitive performance research, particularly in areas involving stress adaptation and neuronal signaling.
Semax should be stored at -20°C prior to reconstitution. Once prepared for research use, refrigerate at 2–8°C and avoid repeated freeze-thaw cycles to maintain peptide stability.
At White Label Research, Semax undergoes third-party HPLC and mass spectrometry testing to verify identity and purity. Certificates of analysis are available on the product page. Our standard threshold is ≥99% purity.
